



SECTION: MEDICAL SCIENCES.

SEKCJA: NAUKI MEDYCZNE.

**How to cite:** Altınöz, E., Akata, E., & Altuner, E. M. (2024). Molecular Docking Application for the Potential use of Palmitic Acid as an AcrB, an Efflux Pump Protein, Inhibitor. *Horizons of Innovation: Conference on Multidisciplinary Trends in Science 2024*. (pp. 352-356). Futurity Research Publishing. <https://futurity-publishing.com/horizons-of-innovation-conference-on-multidisciplinary-trends-in-science-2024-2/>

## MOLECULAR DOCKING APPLICATION FOR THE POTENTIAL USE OF PALMITIC ACID AS AN ACRB, AN EFFLUX PUMP PROTEIN, INHIBITOR

*Eda Altınöz<sup>1\*</sup>, Ilgaz Akata<sup>2</sup>, Ergin Murat Altuner<sup>3</sup>*

<sup>1</sup>*Ph.D. Candidate, Department of Biology, Kastamonu University, Turkey*

<sup>2</sup>*Professor, Ilgaz Akata, Department of Biology, Ankara University, Turkey*

<sup>3</sup>*Professor, Department of Biology, Kastamonu University, Turkey*

[\\*altinozedaa@gmail.com](mailto:*altinozedaa@gmail.com)

**Accepted:** February 22, 2024 | **Published:** February 28, 2024 | **Language:** English

**Abstract:** Studies continue every day with the increase in multi-drug resistance in bacteria. In this study, the effect of potential inhibitors against the efflux pump with natural components in extracts obtained from some macrofungus to increase the effectiveness of antibiotics was investigated with an *in silico* study. Molecular docking was performed on the inhibition effect of palmitic acid against the AcrB (4DX5) protein of the RND pump. As a result of the modelling, it was determined that it had an inhibitory effect, and the binding affinity was  $-2.14 \text{ kcal mol}^{-1}$ . Although palmitic acid may be a promising RND efflux pump inhibitor against multi-drug resistance *Escherichia coli*, further supportive studies are required.

**Keywords:** Efflux pumps, inhibitor, *E. coli*, antibiotic resistance, multi-drug resistance, molecular docking, RND

**Introduction:** The efflux pump, one of the antibiotic resistance mechanisms, has different superfamilies. The RND pump is just one of them (Altınöz & Altuner, 2019; 2022). The research on the Resistance-nodulation-division (RND) family in this study is due to the MDR *E. coli* strains used in the *in vitro* study. RND pump is one of the pump types found in gram-negative bacteria (Ashtiani et al., 2023; Colclough et al., 2020). The RND pump is a characterized efflux pump. It contains the AcrAB-TolC complex. AcrA is a periplasmic adapter protein, AcrB is an inner membrane-embedded protein, and TolC is an outer membrane factor protein (Du et al., 2014; Szal et al., 2023). This study targeted the AcrB (4DX5) protein (Samreen et al., 2023). Apart from the 4DX5 protein, there are also various proteins in different subtypes, such as 2D2R (Yilmaz et al., 2015), 1T9Y, and 1T9U (Rafiq et al., 2018), which belong to the AcrB protein. Before the *in silico* study, *in vitro* studies of this study were performed. In the *in vitro* part of the study, MDR *E. coli* strains with active multidrug-resistant efflux pumps were used (Altınöz & Altuner, 2019, 2020). A combined study with antibiotics was conducted using *Fomes fomentarius* and *Phellinus hartigii* macrofungi extracts. As a result of the *in vitro* study, inhibition was observed. Afterwards, the components were determined by GC/MS analysis of the extracts. The study continued in an *in silico* environment to observe the inhibition effect of the components reflected in the results on the efflux pump. Some of these components were included in the study by applying molecular docking. Palmitic acid is one of them. A study was conducted to observe the effect of palmitic acid inhibition on the RND pump. Since *E. coli* strains were used in the study, the effects of metabolites determined in the fungi extracts on the RND pump were investigated.

Palmitic acid is a common, saturated-free fatty acid. It is also found in the human body as free fatty acid. It is known to be included in traditional Chinese medicine and many foods. In cell experiments regarding palmitic acid, it has been reported that palmitic acid has toxic side effects on organs such as the heart, kidney, liver, and lung. However, there are no reports of this situation in studies conducted on animal models, and it is known that the uncertainty of the toxic mechanism continues (Lv et al., 2023; Pascual et al., 2021; Yuan et al., 2021). When the mechanism of action of palmitic acid is examined, it is stated that the target organelle may be the cell membrane of a virus, fungus, parasite, or bacteria. Palmitic acid has detergent permeable properties. Therefore, the cell membrane may deteriorate, and cell organelles may lose their functionality. Additionally, it is an advantage that palmitic acid has amphipathic properties and can interact with the cell membrane and cell wall. Thus, tiny pores are formed along the cell membrane. As a result, foreign substances cannot enter the organelles of the microorganism and are limited. For this reason, substances cannot be regularly moved into or out of the cell, resulting in osmotic shock. Palmitic acid can also use processes such as enzyme activity inhibition, toxic peroxidation, cell lysis, nutrient uptake, and release to achieve antimicrobial activity (Desbois & Smith, 2010; Johnson & Daniel, 2014; Pohl et al., 2011).


Molecular docking study was carried out using the Autodock 1.5.6 program. The AcrB protein MDR *E. coli* (Protein Data Bank: 4DX5, close monomer) was used to dock with palmitic acid. The 3D crystal AcrB protein structure was downloaded from the protein database in .pdb format (<https://www.rcsb.org/structure/4DX5>). Palmitic Acid 3D conformation (CID: 985) were downloaded from PubChem (<https://pubchem.ncbi.nlm.nih.gov>) in sdf format and converted into pdb file using Open Babel GUI. Ligand and water residues were removed from the receptor protein, and docking analysis was performed. Post-analysis figures were created using Biovia Discovery Studio.

**Research Results:** Considering the data obtained in the *in vitro* section, extract and antibiotic combinations against the MDR *E. coli* strain causing inhibition of the bacteria were applied.

Therefore, it is predicted that the extracts contain components for potential efflux pump inhibitors. Of course, detailed *in vitro* studies on these components will continue. However, as is known, working in an *in silico* environment saves time for experiments to be carried out in an *in vitro* environment. In this study, firstly, molecular docking analysis of palmitic acid, which is thought to have an effect, was performed, and it was studied how the applied compound binds to the AcrB (4DX5) protein of the relevant RND pump as a ligand. Also, GC/MS % data of palmitic acid macrofungus extract results are as follows so; *F.fomentarius* methanol 4.91%, *F.fomentarius* acetone 1.99%, *F.fomentarius* ethyl acetate 1.33%, *P. hartigii* methanol 4.00%, *P. hartigii* acetone 1.00%. Molecular docking results are given in Figure 1, and Figure 2.


**Figure 1**

3D Image Depicting The Interacting Residues For Palmitic Acid-AcrB Interaction



**Figure 2**

Molecular Docked Complex of Palmitic Acid with AcrB (PDB: 4DX5) and general view of AcrB protein (PDB: 4DX5) and Molecular Docked Complex



**Conclusions:** Molecular docking study of the palmitic acid ligand with AcrB (PDB: 4DX5) protein. Although it may be a promising RND efflux pump potential inhibitor against *E. coli*, it should be taken into account that this is a potentially toxic component. Further studies are needed to continue to achieve the goal of re-entering the palmitic acid into the cell and restoring the amount of the drug whose concentration has decreased in the cell.

## References

- Altınöz, E., & Altuner, E. M. (2019). Antibiotic resistance and efflux pumps. *International Journal of Innovative Research and Reviews (INJIRR)*, 3(2), 1–9. <https://dergipark.org.tr/en/download/article-file/995486>
- Altınöz, E., & Altuner, E. M. (2020). Responses of some *Escherichia coli* clinical isolate strains with multiple drug resistance and overexpressed efflux pumps against efflux pump inhibitors. *International Journal of Biology and Chemistry*, 13(1), 77–87. <https://doi.org/10.26577/ijbch.2020.v13.i1.08>
- Altınöz, E., & Altuner, E. M. (2022). Observing the presence of efflux pump activities in some clinically isolated bacterial strains. *International Journal of Biology and Chemistry*, 15(1), 48–54. <https://doi.org/10.26577/ijbch.2022.v15.i1.05>
- Ashtiani, E. E., Gholizadeh Siahmazgi, Z., Mirpour, M., & Soltani, B. M. (2023). RND pump inhibition: in-silico and in-vitro study by Eugenol on clinical strain of *E. coli* and *P. aeruginosa*. *In Silico Pharmacology*, 11, Article 22. <https://doi.org/10.1007/s40203-023-00159-z>
- Colclough, A. L., Alav, I., Whittle, E. E., Pugh, H. L., Darby, E. M., Legood, S. W. ... Blair, J. M. A. (2020). RND efflux pumps in Gram-negative bacteria; Regulation, structure and role in antibiotic resistance. *Future Microbiology*, 15(2), 143–157. <https://doi.org/10.2217/fmb-2019-0235>
- Desbois, A. P., & Smith, V. J. (2010). Antibacterial free fatty acids: Activities, mechanisms of action and biotechnological potential. *Applied Microbiology and Biotechnology*, 85(6), 1629–1642. <https://doi.org/10.1007/s00253-009-2355-3>
- Du, D., Wang, Z., James, N. R., Voss, J. E., Klimont, E., Ohene-Agyei, T. ... Luisi, B. F. (2014). Structure of the AcrAB-TolC multidrug efflux pump. *Nature*, 509(7501), 512–515. <https://doi.org/10.1038/nature13205>
- Johnson, M., & Daniel, A. A. (2014). Occurrence, biochemical, antimicrobial and health effect of palmitic acid. In L. F. Porto (Ed.), *Palmitic acid: Occurrence, biochemistry and health effects* (pp. 17–44). Nova Science Publishers.
- Lv, L., Wang, X., & Wu, H. (2023). Assessment of palmitic acid toxicity to animal hearts and other major organs based on acute toxicity, network pharmacology, and molecular docking. *Computers in Biology and Medicine*, 158, Article 106899. <https://doi.org/10.1016/j.compbiomed.2023.106899>
- Pascual, G., Domínguez, D., Elosúa-Bayes, M., Beckedorff, F., Laudanna, C., Bigas, C., ... & Benitah, S. A. (2021). Dietary palmitic acid promotes a prometastatic memory via Schwann cells. *Nature*, 599(7885), 485–490. <https://doi.org/10.1038/s41586-021-04075-0>
- Pohl, C. H., Kock, J. L. F., & Thibane, V. S. (2011). Antifungal free fatty acids: A review. In A. Méndez-Vilas (Ed.), *Science against microbial pathogens: Current research and technological advances* (61–71). Formatex Research Center.
- Rafiq, Z., Sivaraj, S., & Vaidyanathan, R. (2018). Computational docking in silico analysis of potential efflux pump inhibitor punigratane. *International Journal of Pharmacy and Pharmaceutical Sciences*, 10(3), 27–34.
- Samreen, Qais, F. A., & Ahmad, I. (2023). In silico screening and in vitro validation of phytocompounds as multidrug efflux pump inhibitor against *E. coli*. *Journal of Biomolecular Structure and Dynamics*, 41(6), 2189–2201. <https://doi.org/10.1080/07391102.2022.2029564>

Szal, T., Chauhan, S. S., Lewe, P., Rachad, F., Madre, M., Paunina, L. ... Windshügel, B. (2023). Efflux pump-binding 4 (3-Aminocyclobutyl) Pyrimidin-2-Amines are colloidal aggregators. *Biomolecules*, 13(6), Article 1000. <https://doi.org/10.3390/biom13061000>

Yilmaz, S., Altinkanat-Gelmez, G., Bolelli, K., Guneser-Merdan, D., Ufuk Over-Hasdemir, M., Aki-Yalcin, E., & Yalcin, I. (2015). Binding site feature description of 2-substituted benzothiazoles as potential AcrAB-TolC efflux pump inhibitors in *E. coli*. *SAR and QSAR in Environmental Research*, 26(10), 853–871. <https://doi.org/10.1080/1062936X.2015.1106581>

Yuan, W. ., Huang, Z. R., Xiao, S. J., Zhang W. D, & Shen, Y. D. (2021). Acute toxicity study of flavonoids from *Sophora Tonkinensis Radix et Rhizoma* on zebrafish. *Chinese Traditional and Herbal Drugs*, 52(10), 2978–2986.